Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-616 mimic
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-616 mimic is a synthetic double-stranded RNA molecule designed to replicate the biological activity of endogenous microRNA-616 (miR-616). In the context of prostate cancer research, miR-616 has been identified as an oncomiR that is significantly overexpressed in androgen-independent (AI) prostate cancer compared to androgen-dependent (AD) stages. The mimic is utilized in experimental models to study the oncogenic role of miR-616, which functions by suppressing the expression of the tumor suppressor Tissue Factor Pathway Inhibitor-2 (TFPI-2) through binding to its 3'-untranslated region (UTR). This suppression promotes androgen-independent growth and aggressive phenotypes in prostate cancer cells. While primarily used as a research tool, miRNA mimics represent a class of RNA-based therapeutics aimed at modulating gene expression pathways involved in disease progression.
- Other names
- microRNA-616 mimicmicroRNA616 mimicmicroRNA 616 mimichsa-miR-616 mimichsa-miR616 mimichsa-miR 616 mimic
02
Targets
MYC (MYC proto-oncogene protein)Tissue factor pathway inhibitor 2 (TFPI2) mRNA
Beyond the preview
Go deeper on miR-616 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-616 mimic.